Gene therapy of metastatic disease: Progress and prospects

Surgical Oncology Clinics of North America

Volumn 10, Issue 2, 2001, Pages 449-460

  Maron, D J ^a   Choi, E A ^a   Spitz, F R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PRODRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CANCER; CANCER INHIBITION; CLINICAL TRIAL; GENE THERAPY; HUMAN; IMMUNOPOTENTIATION; LENTIVIRINAE; METASTASIS; ONCOGENE; PROTEIN EXPRESSION; PROTEIN SECRETION; RETROVIRUS; REVIEW; SUICIDE GENE;

EID: 0035017699     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30075-9     Document Type: Review

References (63)

1. Abai A. Hobart P. Barnhart K. Insulin delivery with plasmid DNA Human Gene Therapy 10 1999 2637 2649
2. Anderson S. Johnson D. Harris M. p 53 gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of recombinant adenovirus Clin Cancer Res 4 1998 1649 1659
3. Bao J. Zhang W. Kuno M. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas Human Gene Therapy 7 1996 355 365
4. Bergh J. Norberg T. Sjogren S. Complete sequencing of the p 53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nature Medicine 1 1995 1029 1034
5. Bilboa G. Gomez-Navarro J. Curiel D. Targeted adenoviral vectors for cancer gene therapy Walden Gene Therapy of Cancer 1998 Plenum Press New York 365 373
6. Bischoff J. Kirn D. Williams A. An adenovirus mutant that replicates selectively in p 53-deficient human tumor cells Science 274 1996 373 376
7. Bookstein R. Demers W. Gregory R. p 53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer Semin Oncol 23 1996 66 77
8. Brennan J. Mao L. Hruban R. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck N Engl J Med 332 1995 429 435
9. Brody S. Jaffe H. Wersto R. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors Human Gene Therapy 5 1994 437 447
10. Cai D. Mukhopadhyay T. Liu Y. Stable expression of the wild-type p 53gene in human lung cancer cells after retrovirus mediated gene transfer Human Gene Therapy 4 1993 617 624
11. Caruso M. Pham-Nguyen K. Kwong Y. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci USA 93 1996 11302 11306
12. Chang F. Syrjanen S. Syrjanen K. Implications of the p 53 tumor-supressor gene in clinical oncology J Clin Oncol 13 1995 1009 1022
13. Clayman G. El-Naggar A. Roth J. In vivo molecular therapy with p 53 adenovirus for microscopic residual head and neck squamous carcinoma Cancer Res 55 1995 1 6
14. clayman G. el-Naggar A. Lippman S. Adenovirus-mediated p 53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma J Clin Oncol 16 1998 2221 2232
15. Conry R. LoBuglio A. Kantor J. Immune response to a carcinoembryonic antigen polynucleotide vaccine Cancer Res 54 1994 1164 1168
16. Crystal R. Hirschowitz E. Lieberman M. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine Human Gene Therapy 8 1997 985 1001
17. Culver K. Ram Z. Wallbridge S. In vivo gene transfer with retro-viral vector-producer cells for treatment of experimental brain tumors Science 256 1992 1550 1552
18. Eastham J. Hall S. Sehgal I. In vivo gene therapy with p 53 or p21 adenovirus for prostrate cancer Cancer Research 55 1993 5151 5155
19. Fearon E. Pardoll D. Itaya T. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 60 1990 397 403
20. Freeman S. Ramesh R. Shastri M. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells Cancer Letters 92 1995 167 174
21. Gansbacher B. Bannerji R. Daniels B. Retroviral vector-mediated y-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity Cancer Research 50 1990 7820 7825
22. Gerolami R. Cardoso J. Bralet M. Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery Gene Therapy 5 1998 896 904
23. Goodman J. Trask T. Chen S. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: Pathologic, radiologic, and molecular studies Human Gene Therapy 7 1996 1241 1250
24. Gotoh A. Ko S. Shirakawa T. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer J Urol 160 1998 220 229
25. Guarini A. Gansbacher B. Cronin K. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response Cytokines and Molecular Therapy 1 1995 57 64
26. Guerette B. Moisset P. Huard C. Inflammatory damage following first-generation replication-defective adenovirus controlled by anti-LFA-1 J Leukoc Biol 61 1997 533 538
27. Gunzburg W. Fleuchaus A. Saller R. Retroviral vector targeting for gene therapy Cytokines and Molecular Therapy 2 1996 177 184
28. Habib N. Ding S. el-Masry R. Preliminary report: The short-term effects of direct p 53 DNA injection in primary hepatocellular carcinomas Cancer Detection and Prevention 20 1996 103 107
29. Harada J. Berk A. p 53-independent and -dependent requirements for E1B-55K in aden-ovirus type 5 replication J Virol 73 1999 5333 5344
30. Harris M. Sutjipto S. Wills K. Adenovirus-mediated p 53 gene transfer inhibits the growth of human tumor cells expressing mutant p 53 protein Cancer Gene Therapy 3 1996 121 130
31. Heise C. Sampson-Johannes A. Williams A. ONYX-015 , an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nature Medicine 3 1997 639 644
32. Heise C. Williams A. Xue S. Intravenous administration of ONYX-015 , a selectively replicating adenovirus, induces antitumoral efficacy Cancer Res 59 1999 2623 2628
33. Hortobagyi G. Hung M. Lopez-Berestein G. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer Human Gene Therapy 9 1996 1775 1798
34. Kern S. p 53: Tumor suppression through control of the cell cycle Gastroenterology 106 1994 1708 1710
35. Khil M. Kim J. Mullen C. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in cultured transduced with cytosine deaminase gene Clinical Cancer Research 2 1996 53 57
36. Kim C. Prevette T. Cormier J. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro J Immunother 20 1997 276 286
37. Koebrel D. Alexander I. Halbert C. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors Proc Natl Acad Sci USA 94 1997 1426 1431
38. Kwong Y. Chen S. Kosai K. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer Chest 112 1997 1332 1337
39. Lengyel P. Biochemistry of interferons and their actions Annu Rev Biochem 51 1982 251 282
40. Lowe S. Ruley H. Jacks T. p 53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
41. Morris J. Ramsey W. Wildner O. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma Human Gene Therapy 11 2000 487 503
42. Morse M. Deng Y. Coleman D. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen Clin Cancer Res 5 1999 1331 1338
43. Morse M. Zhou L. Tedder T. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy Ann Surg 226 1997 6 16
44. Mujoo K. Maneval D. Anderson S. Adenoviral-mediated p 53 tumor suppressor gene therapy of human ovarian carcinoma Oncogene 12 1996 1617 1623
45. Muruve D. Barnes M. Stillman I. Adenoviral gene therapy leads to rapid introduction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo Human Gene Therapy 10 1999 965 976
46. Nabel E. Gordon D. Yang Z. Gene transfer in vivo with DNA-liposome complexes: Lack of autoimmunity and gonadel localization Human Gene Therapy 3 1992 649 659
47. Nielsen L. Maneval D. p 53 tumor supressor gene therapy for cancer Cancer Gene Therapy 5 1998 52 63
48. O’Reilly M. Boehm T. Shing Y. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277 285
49. Otake K. Ennist D. Harrod K. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses Human Gene Therapy 9 1998 2207 2222
50. Philip R. Clary B. Brunette E. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer Clin Cancer Res 2 1996 59 68
51. Poeschla E. Gilbert J. Li X. Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2 based lentivirus vectors J Virol 72 1998 6527 6536
52. Rosenberg S. Zhai Y. Yang J. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gplOO melanoma antigens J Natl Cancer Inst 90 1998 1894 1900
53. Roth J. Cristiano R. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 89 1997 21 39
54. Sauter B. Martinet O. Zhang W. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases Proc Natl Acad Sci USA 97 2000 4802 4807
55. Sikorski R. Peters R. Gene therapy: Treating with HIV Science 282 1998 1438 1441
56. Sobol R. Shawler D. Carson C. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A phase I study Clin Cancer Res 5 1999 2359 2365
57. Spitz F. Nguyen D. Skibber J. Adenoviral-mediated wild-type p 53 gene expression sensitizes colorectal cancer cells to ionizing radiation Clin Cancer Res 2 1996 1665 1671
58. Spitz F. Nguyen D. Skibber J. In vivo adenovirus-mediated p 53 tumor suppressor gene therapy for colorectal cancer Anticancer Res 16 1996 3415 3422
59. Swisher S. Roth J. Nemunaitis J. Adenovirus-mediated p 53 gene transfer in advanced non-small-cell lung cancer J Natl Cancer Inst 91 1999 763 771
60. Ueno N. Hung M. Weiden P. Phase I E1A gene therapy in patients with advanced breast and ovarian cancers Proc Am Soc Clin Oncol 17 1998 432a abstract 1663
61. Wildner O. Morris J. Vahanian N. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer Gene Therapy 6 1999 57 62
62. Yu D. Chen Y. Seng M. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res 59 1999 4200 4203
63. Yu D. Matin A. Xia W. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu Oncogene 11 1995 1383 1388